InVision Medical Technology vs Isomorphic Labs

Side-by-side comparison of features, pricing, and ratings

Analysis reviewed Live tool data as of 2026-08-23
Cross-checked through our multi-step verification ·
Saved

At a glance

DimensionInVision Medical TechnologyIsomorphic Labs
PricingContact sales (enterprise)Contact sales (pharma partnerships)
Primary ApplicationAI for echocardiography (LVEF, cardiac amyloid)AI for drug discovery (AlphaFold-based)
Regulatory ValidityFDA 510(k) clearance, CPT code, peer-reviewedPre-clinical R&D, no regulatory submissions
Deployment ModelDICOM-native, PACS/EHR integrated, post-processingAI drug design engine via collaborations
Target CustomerHealth systems, cardiology departmentsLarge pharma companies
Latest FundingNot disclosed$600M external round (2025)

InVision Medical Technology and Isomorphic Labs serve entirely different markets. InVision provides clinically deployed, FDA-cleared AI that reduces sonographer workload and detects cardiac amyloidosis in existing echo workflows, with clear reimbursement. Isomorphic Labs is a research-stage drug discovery AI that partners only with large pharma. For a health system seeking immediate ROI through regulatory-approved AI with CPT billing, InVision is the clear choice. Isomorphic Labs is irrelevant for clinical imaging operations.

InVision Medical Technology
InVision Medical Technology

FDA-cleared AI for echocardiography: LVEF, amyloid detection, and beyond.

Visit Website
Isomorphic Labs
Isomorphic Labs

AI-first drug discovery partner built on Nobel-winning AlphaFold.

Visit Website
Pricing
Contact Sales
Contact Sales
Plans
Popularity
3 views
7.4k views
Skill Level
Intermediate
Advanced
API Available
Platforms
WebAPI
Categories
🏥 Healthcare
🧬 Drug Discovery & Life Sciences
Features
Automated LVEF calculation
AI detection of cardiac amyloidosis
FDA 510(k) clearance for Precision LVEF and Precision Cardiac Amyloid
Prospective randomized controlled trial published in Nature (2023)
DICOM-native post-processing
Vendor-neutral: GE, Philips, Siemens, Canon, handheld POCUS
PACS and Epic EHR integration
CPT Category III code 0932T (effective Jan 1, 2025)
Medicare NTAP for inpatient amyloid (up to $2,275/stay, Oct 1, 2026)
Breakthrough Device designation for cardiac amyloid
FDA TAP enrollment
Zero marginal clinician burden per study
Multi-indication pipeline (LVEF, amyloid, cirrhosis, reporting, valve disease)
Precision Cirrhosis for opportunistic liver disease detection
Precision Reporting with EchoPrime foundation model
Built on Nobel-winning AlphaFold system
Generative AI molecule design via Drug Design Engine
Predictive AI models for protein-ligand interactions
Digital biology simulation at scale
End-to-end drug discovery from target ID to lead optimization
Partnership model with Novartis and Johnson & Johnson
Drug metabolism and toxicity simulation
Bioresilience framework for pandemic preparedness
US operations established in 2025
Series B funding in February 2026
Max Jaderberg appointed as President
Dr. Ben Wolf appointed as Chief Medical Officer
Interdisciplinary team of ML and drug discovery experts
Integrations
PACS
Epic EHR
CVIS

What real users say: InVision Medical Technology vs Isomorphic Labs

Not marketing copy and not our opinion — a structured sweep of public discussion (reviews, forums, communities and video comments), showing what people praise and what they complain about for each tool.

InVision Medical Technology

0 mentions · mixed

What users praise

  • FDA-cleared for LVEF and cardiac amyloid detection
  • Clinically validated in Nature, Nature Medicine, JAMA
  • Integrates with PACS, Epic EHR, DICOM workflows
  • No new hardware required – works with existing scanners

What frustrates them

  • No real-world user testimonials or community reviews
  • High enterprise cost with no public pricing information
  • Narrow focus on echocardiography limits applicability
  • Unproven in varied clinical settings outside research

Researched Jul 3, 2026

Isomorphic Labs

48 mentions across 3 sources · 82% positive

Hacker News, YouTube, Lemmy

What users praise

  • Built on the Nobel-winning AlphaFold, giving it instant credibility in structural biology.
  • Drug Design Engine extends beyond structure to generative molecule design, promising novel chemistry.
  • Deep partnerships with Novartis and J&J, with potential billions in royalties.
  • Interdisciplinary team of top ML and drug discovery experts, ensuring depth of expertise.

What frustrates them

  • Not accessible to individual researchers or small biotech due to partnership model only.
  • Proprietary nature of parts of its tech limits community scrutiny and independent validation.
  • CASP16 results suggest AlphaFold 3-based models aren't always better than older methods for protein-ligand interactions.
  • No marketed drugs yet; outcomes remain uncertain with royalties tied to long timelines.

Researched Aug 18, 2026

Who should pick which

  • Health system CMO
    Pick: InVision Medical Technology

    InVision provides FDA-cleared, CPT-billable AI that integrates with existing PACS and EHR, reducing sonographer time and improving diagnostic consistency.

  • Chief of Cardiology
    Pick: InVision Medical Technology

    Standardize LVEF measurements across multiple sites and screen for undiagnosed cardiac amyloidosis without new hardware.

  • Big Pharma R&D head
    Pick: Isomorphic Labs

    Isomorphic Labs offers AlphaFold-based drug design engine and predictive models, suited for large-scale lead optimization and novel molecule generation via partnership.

  • Independent echocardiography lab
    Pick: InVision Medical Technology

    Even for smaller groups, InVision's DICOM-native post-processing can improve turnaround and measurement reproducibility, though enterprise procurement may be required.

  • Academic research lab (drug discovery)
    Pick: Isomorphic Labs

    Isomorphic Labs collaborates with large pharma, not individual labs; not accessible for independent researchers.

Frequently Asked Questions

InVision Medical Technology vs Isomorphic Labs: which should you choose?

InVision Medical Technology and Isomorphic Labs serve entirely different markets. InVision provides clinically deployed, FDA-cleared AI that reduces sonographer workload and detects cardiac amyloidosis in existing echo workflows, with clear reimbursement. Isomorphic Labs is a research-stage drug discovery AI that partners only with large pharma. For a health system seeking immediate ROI through regulatory-approved AI with CPT billing, InVision is the clear choice. Isomorphic Labs is irrelevant for clinical imaging operations.

Is InVision Medical Technology FDA approved?

Yes, InVision has FDA 510(k) clearance for Precision LVEF and Precision Cardiac Amyloid.

Does Isomorphic Labs have any FDA-cleared products?

No, Isomorphic Labs is a pre-clinical drug discovery AI company with no FDA-cleared products.

Can I try InVision Medical Technology for free?

No, InVision requires contacting sales for enterprise pricing; no self-service or free trial available.

How does Isomorphic Labs price its AI?

Isomorphic Labs operates through pharma partnerships with undisclosed deal values; no per-use or subscription pricing.

What integrations does InVision support?

InVision integrates with PACS, Epic EHR, and structured reporting platforms, processing standard DICOM studies.

Is Isomorphic Labs available as a software product?

No, Isomorphic Labs is not a standalone product; it partners with pharma companies for collaborative drug discovery.

Does InVision have published clinical validation?

Yes, InVision's algorithms have been published in Nature, Nature Medicine, JAMA Cardiology, and NEJM AI.

What recent funding has Isomorphic Labs raised?

Isomorphic Labs announced a $600M external investment round in 2025 and a Series B in February 2026 (amount undisclosed).

More InVision Medical Technology or Isomorphic Labs comparisons

Explore each tool further

Browse these categories

Still deciding? Get the weekly AI tools brief

One email a week — new tools, honest comparisons, no spam.

Last reviewed: July 3, 2026